Table 2 Number of patients with treatment–emergent AEs by severity regardless of relationship to study drug (for ⩾10% of subjects, n=40)
From: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Preferred term | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Fatigue | 12 (30.0%) | 7 (17.5%) | — | — |
Nausea | 9 (22.5%) | 4 (10.0%) | 1 (2.5%) | — |
Diarrhoea | 12 (30.0%) | — | — | — |
Pyrexia | 8 (20.0%) | 2 (5.0%) | 1 (2.5%) | — |
Oedema peripheral | 7 (17.5%) | 3 (7.5%) | — | — |
Anorexia | 6 (15.0%) | 2 (5.0%) | — | — |
Constipation | 5 (12.5%) | 3 (7.5%) | — | — |
Upper respiratory tract infection | 4 (10.0%) | 3 (7.5%) | 1 (2.5%) | — |
Vomiting | 4 (10.0%) | 3 (7.5%) | 1 (2.5%) | — |
Back pain | 1 (2.5%) | 4 (10.0%) | 2 (5.0%) | — |
Cough | 6 (15.0%) | 1 (2.5%) | — | — |
Abdominal pain | 2 (5.0%) | 1 (2.5%) | 3 (7.5%) | — |
Dizziness | 6 (15.0%) | — | — | — |
Dyspnoea | 4 (10.0%) | 1 (2.5%) | — | 1 (2.5%) |
Chills | 5 (12.5%) | — | — | — |
Dyspepsia | 4 (10.0%) | 1 (2.5%) | — | — |
Headache | 3 (7.5%) | 1 (2.5%) | 1 (2.5%) | — |
Lymph node pain | 4 (10.0%) | 1 (2.5%) | — | — |
Pain in extremity | 2 (5.0%) | 2 (5.0%) | 1 (2.5%) | — |
Pruritus | 3 (7.5%) | 2 (5.0%) | — | — |
Weight decreased | 4 (10.0%) | 1 (2.5%) | — | — |
Anaemia | — | 2 (5.0%) | 2 (5.0%) | — |
Asthenia | 4 (10.0%) | — | — | — |
Hyperglycaemia | 1 (2.5%) | 3 (7.5%) | — | — |
Muscle spasms | 3 (7.5%) | 1 (2.5%) | — | — |
Insomnia | 4 (10%) | — | — | — |
